Whatman

Global Dried Blood Spot Collection Cards Market Report to 2030 - Use Of DBS Cards In Newborn Screening is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 8, 2022

The global dried blood spot collection cards market size is expected to reach USD 517.2 million by 2030, expanding at a CAGR of 4.2% from 2022 to 2030.

Key Points: 
  • The global dried blood spot collection cards market size is expected to reach USD 517.2 million by 2030, expanding at a CAGR of 4.2% from 2022 to 2030.
  • In addition, the WHO recently recommended dried blood spot collection cards for diagnosis of HIV and hepatitis B & C due to the benefits of DBS in collecting blood and transport.
  • Moreover, dried blood spot collection cards have been used in a variety of toxicology applications, including toxicokinetics, epidemiological, environmental, and forensic toxicology.
  • The increase in the adoption of dried blood spot collection cards for therapeutic drug monitoring is a major factor expected to boost market growth in the near future.

Introducing Cytiva - Global Life Sciences Leader

Retrieved on: 
Wednesday, April 1, 2020

- Previously GE Healthcare Life Sciences, Cytiva will help accelerate growth and innovation in biological therapies

Key Points: 
  • - Previously GE Healthcare Life Sciences, Cytiva will help accelerate growth and innovation in biological therapies
    - Leading life sciences brands such as KTA, Amersham, HyClone, MabSelect and Whatman are part of Cytiva
    AMERSHAM, United Kingdom, April 1, 2020 /PRNewswire/ -- Cytiva, a global provider of technologies and services that help advance and accelerate the development and manufacture of therapeutics, launches today.
  • Previously GE Healthcare Life Sciences, Cytiva has nearly 7,000 employees and operations in 40 countries and is part of the Danaher Corporation Life Sciences platform.
  • Emmanuel Ligner, President of Cytiva, says: "Our foundation of scientific expertise, our team, and our solid customer base place Cytiva in the right position to invest, develop, and accelerate growth in the industry.
  • Cytiva is a 3.3 billion USD global life sciences leader with nearly 7000 associates operating in 40 countries dedicated to advancing and accelerating therapeutics.

Introducing Cytiva - Global Life Sciences Leader

Retrieved on: 
Wednesday, April 1, 2020

- Previously GE Healthcare Life Sciences, Cytiva will help accelerate growth and innovation in biological therapies

Key Points: 
  • - Previously GE Healthcare Life Sciences, Cytiva will help accelerate growth and innovation in biological therapies
    - Leading life sciences brands such as KTA, Amersham, HyClone, MabSelect and Whatman are part of Cytiva
    AMERSHAM, United Kingdom, April 1, 2020 /PRNewswire/ -- Cytiva, a global provider of technologies and services that help advance and accelerate the development and manufacture of therapeutics, launches today.
  • Previously GE Healthcare Life Sciences, Cytiva has nearly 7,000 employees and operations in 40 countries and is part of the Danaher Corporation Life Sciences platform.
  • Emmanuel Ligner, President of Cytiva, says: "Our foundation of scientific expertise, our team, and our solid customer base place Cytiva in the right position to invest, develop, and accelerate growth in the industry.
  • Cytiva is a 3.3 billion USD global life sciences leader with nearly 7000 associates operating in 40 countries dedicated to advancing and accelerating therapeutics.